Skip to content

Study · Animal study (in vivo) · mouse and rat · 2004

12 results

Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.

Lovric-Bencic M, Sikiric P, Hanzevacki JS, Seiwerth S, Rogic D, Kusec V, Aralica G, Konjevoda P, Batelja L, Blagaic AB

Journal of pharmacological sciences1 May 2004Cited by 70 (Europe PMC)

PMID15153646 (opens in a new tab)DOI10.1254/jphs.95.19 (opens in a new tab)PepBankPUB-15153646
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with doxorubicin-induced heart failure, BPC157 at 10 microg/kg reversed the increased big endothelin-1 level.

    In plain wordsIn rats with heart failure, BPC157 reversed the raised big endothelin-1 level seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseBig endothelin-1 (BET-1) plasma level, rats
    Study

    ratn: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg per day · intragastric · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with doxorubicin-induced heart failure, BPC157 at 10 microg/kg reversed the increased big endothelin-1 level.

    In plain wordsIn mice with heart failure, BPC157 reversed the raised big endothelin-1 level seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseBig endothelin-1 (BET-1) plasma level, mice
    Study

    mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg per day · drinking water · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats and mice with doxorubicin-induced heart failure, BPC157 at 10 microg/kg reversed the increased AST value.

    In plain wordsIn rats and mice with heart failure, BPC157 reversed the raised AST enzyme level seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseAST plasma level
    Study

    rat, mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg per day · intragastric (rats) or drinking water (mice) · 14 daysAs given in this study (rat, mouse).

    Source sentences

    Summary
    BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats and mice with doxorubicin-induced heart failure, BPC157 at 10 microg/kg reversed the increased ALT value.

    In plain wordsIn rats and mice with heart failure, BPC157 reversed the raised ALT enzyme level seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseALT plasma level
    Study

    rat, mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg per day · intragastric (rats) or drinking water (mice) · 14 daysAs given in this study (rat, mouse).

    Source sentences

    Summary
    BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with doxorubicin-induced heart failure, BPC157 at 10 microg/kg reversed the increased CK value.

    In plain wordsIn rats with heart failure, BPC157 reversed the raised CK enzyme level seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseCK plasma level, rats
    Study

    ratn: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg per day · intragastric · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with doxorubicin-induced heart failure, BPC157 at 10 microg/kg reversed the increased CK value.

    In plain wordsIn mice with heart failure, BPC157 reversed the raised CK enzyme level seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseCK plasma level, mice
    Study

    mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg per day · drinking water · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with doxorubicin-induced heart failure, BPC157 at 10 microg/kg reversed the increased LDH value.

    In plain wordsIn mice with heart failure, BPC157 reversed the raised LDH enzyme level seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseLDH plasma level, mice
    Study

    mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg per day · drinking water · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with doxorubicin-induced heart failure, BPC157 at 10 ng/kg opposed the further increase of big endothelin-1 seen in controls.

    In plain wordsIn rats with heart failure, BPC157 stopped big endothelin-1 from rising further, unlike in controls.

    Peptide
    BPC-157
    Outcome
    No significant changeBig endothelin-1 (BET-1) plasma level, rats, 10 ng/kg
    Study

    ratn: not reported in source

    Doxorubicin-induced congestive heart failure
    Comparator
    Controls (distilled water or drinking water)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg per day · intragastric · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    BPC157 (10 ng/kg) and losartan opposed further increase of BET-1 (rats, mice).
    2 context sentences
    Summary · context
    Controls (distilled water (5 ml/kg, i.g., once daily) or drinking water (2 ml/mouse per day) given throughout 14 days) exhibited additionally increased BET-1 and aggravated clinical status, while enzyme values maintained their initial increase
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice with doxorubicin-induced heart failure, BPC157 at 10 ng/kg opposed the further increase of big endothelin-1 seen in controls.

    In plain wordsIn mice with heart failure, BPC157 stopped big endothelin-1 from rising further, unlike in controls.

    Peptide
    BPC-157
    Outcome
    No significant changeBig endothelin-1 (BET-1) plasma level, mice, 10 ng/kg
    Study

    mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Comparator
    Controls (distilled water or drinking water)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg per day · drinking water · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    BPC157 (10 ng/kg) and losartan opposed further increase of BET-1 (rats, mice).
    2 context sentences
    Summary · context
    Controls (distilled water (5 ml/kg, i.g., once daily) or drinking water (2 ml/mouse per day) given throughout 14 days) exhibited additionally increased BET-1 and aggravated clinical status, while enzyme values maintained their initial increase
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats and mice with doxorubicin-induced heart failure, BPC157 at 10 ng/kg reduced AST serum values.

    In plain wordsIn rats and mice with heart failure, BPC157 lowered AST enzyme levels from the levels seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseAST serum level, 10 ng/kg
    Study

    rat, mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg per day · intragastric (rats) or drinking water (mice) · 14 daysAs given in this study (rat, mouse).

    Source sentences

    Summary
    BPC157 (10 ng/kg) reduces AST and ALT serum values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats and mice with doxorubicin-induced heart failure, BPC157 at 10 ng/kg reduced ALT serum values.

    In plain wordsIn rats and mice with heart failure, BPC157 lowered ALT enzyme levels from the levels seen before treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseALT serum level, 10 ng/kg
    Study

    rat, mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg per day · intragastric (rats) or drinking water (mice) · 14 daysAs given in this study (rat, mouse).

    Source sentences

    Summary
    BPC157 (10 ng/kg) reduces AST and ALT serum values.
    1 context sentence
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In rats and mice with doxorubicin-induced heart failure, the clinical status improved with the BPC157 regimens.

    In plain wordsIn rats and mice with heart failure, the clinical signs got better with BPC157 regimens.

    Peptide
    BPC-157
    Outcome
    DecreaseClinical signs of heart failure (hypotension, heart rate, respiratory rate, ascites)
    Study

    rat, mousen: not reported in source

    Doxorubicin-induced congestive heart failure
    Comparator
    Controls (distilled water or drinking water)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 microg/kg and 10 ng/kg per day · intragastric (rats) or drinking water (mice) · 14 daysAs given in this study (rat, mouse).

    Source sentences

    Summary
    Clinical status of CHF-rats and -mice is accordingly improved by the BPC157 regimens and amlodipine.
    2 context sentences
    Summary · context
    Assessed were big endothelin-1 (BET-1) and plasma enzyme levels (CK, MBCK, LDH, AST, ALT) before and after 14 days of therapy and clinical status (hypotension, increased heart rate and respiratory rate, and ascites) every 2 days.
    Summary · context
    doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.